Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections - Seite 3
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.
About the Unyvero System
The CE-marked Unyvero System is a versatile hardware platform for the detection of a broad panel of bacteria, fungi and antibiotic resistance genes from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result. It is marketed in Europe, Russia, the Middle East and various other non-European countries, with three CE-marked Unyvero Application Cartridges currently available: The Unyvero P55 Cartridge focuses on pneumonia testing, the ITI Cartridge is designed for the diagnosis of implant & tissue infections and the BCU Cartridge is designed to analyze positively flagged blood culture samples from bottles inoculated with blood from patients with suspected blood stream infections. Cartridges for additional indications are in various stages of development and preparation.
In the U.S., Curetis is running a prospective multi-center clinical trial aimed at achieving FDA clearance registered here.
The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only a few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure. Thereby, clinically relevant information is available within about four to five hours to support an informed therapy decision as early as possible.
For further information, please visit www.unyvero.com.
Lesen Sie auch
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.